Currently out of the existing stock ratings of Eva Fortea Verdejo, 2 are a SELL (3.39%), 14 are a HOLD (23.73%), 43 are a BUY (72.88%).

Eva Fortea Verdejo

Work Performance Price Targets & Ratings Chart

Analyst Eva Fortea Verdejo, currently employed at WELLS FARGO, has had 59.64% of price targets met with an average potential upside of 39.42%, reached in 129 days on average.

Eva Fortea Verdejo has documented 118 price targets and ratings displayed on 14 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on BCAX, at 12-Aug-2026.

Wall Street Analyst Eva Fortea Verdejo

Analyst best performing recommendations are on RCUS (ARCUS BIOSCIENCES).
The best stock recommendation documented was for ZYME (ZYMEWORKS) on 11/19/2025. The price target of $25 was fulfilled within 6 days with a profit of $2.4 (10.62%), with a performance score of 17.7.

Average potential price target upside

BCAX IDYA ITOS KNSA Kiniksa Pharmaceuticals Ltd MRUS PTCT PTC Therapeutics RCUS Arcus Biosciences RLAY RVMD XNCR Xencor ZYME Zymeworks CELC Celcuity LLC EXEL NUVL

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 06-Dec-2024

$36

$25.98 (259.28%)

$42

5 days ago
(11-Nov-2026)

Buy Since 08-Oct-2024

$43

$32.98 (329.14%)

$46

6 days ago
(10-Nov-2026)

Buy Since 08-Jan-2026

$37

$26.98 (269.26%)

$39

6 days ago
(10-Nov-2026)

Buy Since 08-Oct-2024

$30

$19.98 (199.40%)

$39

6 days ago
(10-Nov-2026)

Hold Since 31-Mar-2026

$8

$-2.02 (-20.16%)

$20

17 days ago
(30-Oct-2026)

4/4 (100%)

$-1.13 (-12.38%)

100

Show more analysts

Please expand the browser size to see the chart

Which stock is Eva Fortea Verdejo most bullish on?

Potential upside of $101.63 has been obtained for CELC (CELCUITY LLC)

Which stock is Eva Fortea Verdejo most reserved on?

Potential downside of -$22.33 has been obtained for KNSA (KINIKSA PHARMACEUTICALS LTD)

What Year was the first public recommendation made by Eva Fortea Verdejo?

On 2024
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?